Schizophrenia On December 20, 2019, the United States Food and Drug Administration (FDA) approved<unk>  for the treatment of schizophrenia in adults. Bipolar depression In December 2021, the FDA approved<unk>  for the treatment of bipolar depression in adults as monotherapy and as adjunctive therapy with lithium or valproate.
Lumateperone
Tolperisone
Buffalopox
Tesofensine
Bremazocine
Eptazocine
Cidoxepin
Clorotepine